Madelung's disease is a dubious disease in the field of autoimmune and rheumatic immunity, with complex clinical outcomes that often involve multi-systemic burdens. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging checks, laboratory tests and pathological activation.
The platform can help align teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that were previously difficult to treat have been significantly improved. Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely schemes according to changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of Madelung disease. The platform serves the China International Medical Service System, a team of domestic and foreign experts with authority in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.